TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

doi:10.1056/NEJMoa1605949

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

The New England journal of medicine - 24 Nov 2016

Welch John S, Petti Allegra A, Miller Christopher A, Fronick Catrina C, O'Laughlin Michelle, Fulton Robert S, Wilson Richard K, Baty Jack D, Duncavage Eric J, Tandon Bevan, Lee Yi-Shan, Wartman Lukas D, Uy Geoffrey L, Ghobadi Armin, Tomasson Michael H, Pusic Iskra, Romee Rizwan, Fehniger Todd A, Stockerl-Goldstein Keith E, Vij Ravi, Oh Stephen T, Abboud Camille N, Cashen Amanda F, Schroeder Mark A, Jacoby Meagan A, Heath Sharon E, Luber Kierstin, Janke Megan R, Hantel Andrew, Khan Niloufer, Sukhanova Madina J, Knoebel Randall W, Stock Wendy, Graubert Timothy A, Walter Matthew J, Westervelt Peter, Link Daniel C, DiPersio John F, Ley Timothy J

Abstract excerpt

BACKGROUND: The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. METHODS: We enrolled 84 adult patients with AML or MDS in a single-institution trial of decitabine to identify somatic mutations and their relationships to clinical responses. Decitabine was administered at a dose of 20 mg per square meter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 5-Methylcytosine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antimetabolites, Antineoplastic

Share to Myelodysplastic Syndromes

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 27959731
DOI: 10.1056/NEJMoa1605949
PMCID: PMC5217532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.PMID 27959731Read ↗

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity Read ↗

[The Epigenetic Regulation of Decitabine Resistance in TP53 -Mutated Myelodysplastic Syndromes: Integrated Analysis Based on RNA-seq and Methylomics].Semantic proximity Read ↗

Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome.Semantic proximity Read ↗

High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Challenges of Complex Karyotype and TP53 MutationSemantic proximity Read ↗

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.Semantic proximity Read ↗

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read ↗

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialSemantic proximity Read ↗

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.Semantic proximity Read ↗

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).Semantic proximity Read ↗

Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation.Semantic proximity Read ↗

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.